BRCA1/2 Genetic Testing — Body Handbook

სკრინინგი · §104

BRCA1/2 Genetic Testing

If your aunt died of ovarian cancer at 48 and your grandmother had breast cancer at 42, this test is the lever. A pathogenic BRCA1 or BRCA2 variant pushes lifetime breast cancer risk to roughly 60–80% and ovarian cancer risk to 17–44%, and carriers who act on the result cut their odds of dying before 70 by about three-quarters. The test is one blood draw and a couple of conversations; the weight is in deciding to take it, then acting on what it says.

გადაწყვიტე · ერთხელ მტკიცებულება ძლიერი თავი სკრინინგი

For the right person, this is one of the largest single levers in cancer prevention — a one-time test that, when positive and acted on, drops early mortality by roughly three-quarters and reshapes the next forty years of screening and surgery. For everyone else in the family, one positive result turns a 50/50 guess into a cheap, definitive answer for each relative. The cost is small money and a couple of clinic hours; the hard part is deciding to ask.

Every cell carries two copies of every gene. BRCA1 and BRCA2 are repair-crew genes — when DNA snaps under normal wear and tear, the proteins they code for stitch it back together correctly. A pathogenic variant is a broken copy you inherit from one parent at conception, present in every cell, for life. The cell is fine: the other copy handles repair. But across decades of cell division in breast and ovarian tissue, the working copy eventually breaks too in some cell. With no functional repair left in that cell, DNA damage piles up and a tumour starts. That's why the risk is high — the second hit is statistically near-certain over a lifetime — and stochastic: which cell, which decade, nobody knows.

The same broken-repair logic is why BRCA-mutated tumours are uniquely vulnerable to a class of drugs called PARP inhibitors. The drug blocks a backup repair pathway; in a cell already missing its main one, the damage compounds and the cell dies. Healthy cells, still carrying the working BRCA copy, survive. The test result therefore does two things at once: it changes prevention before a diagnosis, and it changes treatment options if one comes Robson 2017.

The numbers

A woman with a pathogenic BRCA1 variant has roughly a 72% chance of breast cancer by age 80 and a 44% chance of ovarian cancer. The numbers for BRCA2 are 69% and 17%. Compare with the general-population baseline of roughly 13% breast and 1.3% ovarian.

The mortality numbers — what actually matters — come from carriers who acted on a positive result. Removing the ovaries and fallopian tubes before menopause cut all-cause mortality before 70 by roughly three-quarters Finch 2014; in a separate cohort it cut ovarian-cancer-specific mortality by 79% and breast-cancer-specific mortality by more than half Domchek 2010. Risk-reducing mastectomy reduced subsequent breast cancer by over 90% Hartmann 1999. For carriers already diagnosed, an oral drug called olaparib improved three-year disease-free survival in early breast cancer from 77.1% to 85.9% Tutt 2021.

Who should actually ask for the test

Most people shouldn't. BRCA carriers are roughly 1 in 400 in the general population, and population-wide testing isn't yet standard practice. The American and British guideline bodies converge on a specific list of triggers — if any of these match you or a close blood relative, you should be talking to a genetic counsellor:

Breast cancer diagnosed at or before age 50
Triple-negative breast cancer at any age (or under 60 by some criteria)
Male breast cancer at any age
Ovarian, fallopian-tube, or primary peritoneal cancer at any age
Metastatic prostate cancer, or pancreatic cancer, at any age
Two or more close relatives with any of the above on the same side of the family
A known pathogenic BRCA1/2 variant already identified in a relative
Ashkenazi Jewish ancestry plus a personal or family history of any of the above

The counsellor's job is to translate that list into your specific family tree and decide whether a test is indicated USPSTF 2019 NCCN v3.2024. If you're a first-degree relative of someone with a known pathogenic variant — sibling, parent, child — your decision is simpler: your prior probability is 50%, and the test in your case is a single, cheap, definitive check for that one variant. That's the cascade-testing pathway, and it's the most cost-effective cancer-prevention move in the entire literature Manchanda 2015.

What skipping the test actually costs

Anchor on the realistic case. A woman in her late thirties whose mother had breast cancer at 45 and whose maternal aunt had ovarian cancer at 52. She qualifies for testing. She doesn't ask. The next ten years are quietly different in two ways. She and her doctor screen by family-history rules rather than by carrier rules — yearly mammogram from 40 instead of yearly MRI plus mammogram alternating every six months from her late twenties. A small early breast tumour that an MRI would have caught at year three gets caught by mammogram at year six, when it's larger and the treatment plan is harder.

More serious: nobody removes her ovaries. Ovarian cancer has no effective screening test; it presents late, and most diagnoses are stage III or IV with five-year survival under half. If she's a BRCA1 carrier, her lifetime ovarian risk sits around 44%, and the median age at diagnosis in carriers falls in the fifties Kuchenbaecker 2017 Finch 2014.

The family side is the part she might not picture. Her two sisters and her teenage daughter inherit the same 50% prior probability she had — and they inherit it unanswered. A test she could have taken at 38, paid for by insurance and returned in three weeks, would have let each of them get a fast, single-variant check the next year. Without her test, every relative carries the same unresolved weight forward into their own forties.

What the testing pathway looks like

The clinical pathway is almost entirely paperwork.

The lab almost always runs a multi-gene panel, not just BRCA1/2 alone — PALB2, CHEK2, ATM, TP53 and a dozen others come along at no extra cost, and any of them changes management if found NCCN v3.2024. Three result categories exist. Pathogenic or likely pathogenic is what the rest of this article calls a positive. Negative only fully reassures if a specific family variant was known beforehand and you don't have it (a "true negative"); if no family variant was known, your test is "uninformative" and your family-history risk is unchanged. Variant of uncertain significance means the lab found a change it can't yet classify — it is treated as negative until reclassified, and it should not drive surgical decisions.

For a confirmed carrier, the surveillance and surgery calendar shifts dramatically. Annual breast MRI starts at 25 for BRCA1 and 25–30 for BRCA2; an annual mammogram joins at 30, and the two are typically alternated every six months so imaging happens twice a year. There is no equivalent surveillance for ovarian cancer — the recommended move is to remove the ovaries and fallopian tubes between 35 and 40 for BRCA1 carriers and 40–45 for BRCA2, after childbearing is complete Saslow 2007 NCCN v3.2024. Risk-reducing mastectomy is offered, not required; carriers who choose intensive surveillance plus oophorectomy do well on that path too. Men with BRCA2 add yearly prostate screening from 40 and watch for breast changes.

What most people get wrong

"No family history of cancer, so this isn't about me." Up to half of identified BRCA carriers would be missed by family-history-only criteria Manchanda 2015. New mutations happen, fathers transmit the gene at the same rate as mothers, and small or scattered families hide inheritance patterns.
"I already did 23andMe and it was clear." The 23andMe BRCA test reports three founder variants common in Ashkenazi populations FDA 2018. Outside that ancestry, those three account for under 0.1% of pathogenic BRCA findings. A negative 23andMe result is uninformative for nearly everyone else; a positive one still needs a clinical confirmation test before any decision.
"This is a women's test." Men with a BRCA2 variant carry roughly 7% lifetime breast cancer risk and around 20% lifetime risk of an aggressive prostate cancer. Pancreatic cancer risk is raised in both sexes. Fathers and brothers belong in the conversation NCCN v3.2024.
"A negative test means I'm in the clear." Only if a known family variant was being checked. Without that anchor, the test rules out only the specific inherited risk it can read — it doesn't erase the family pattern.
"Surgery is the only option." Intensive surveillance (MRI plus mammogram) plus ovary removal in your late thirties is a legitimate path; many carriers take it and outcomes are good with adherence.

When not to test, and what to settle first

The test itself has no medical contraindications — it's a tube of blood or saliva. The "don'ts" are about timing, ordering, and what to do with the result.

Don't test minors for adult-onset cancer predisposition. The medical genetics consensus is to wait until the person can consent and act on the result themselves — there's no childhood intervention to take.
Don't skip the pre-test counselling. A positive result without a plan around it drives surgical decisions made under panic, family disclosures that go badly, and insurance choices made without good information.
Treat a direct-to-consumer "BRCA: variant not detected" as no test at all unless you have Ashkenazi Jewish ancestry — the assay reads three variants out of thousands FDA 2018.
Know the insurance gap. In the US, the Genetic Information Nondiscrimination Act blocks health insurance and employment discrimination based on a positive result; it does not cover life, disability, or long-term-care insurance. If you intend to buy those products, time the purchase before the test, not after.

What it actually costs and where to go

In the US, a clinical multi-gene panel runs roughly $250 to $500 cash-pay through Invitae, Ambry, or Color, and is routinely covered by insurance when the eligibility criteria above are met — meaning the typical out-of-pocket for an indicated patient is closer to a copay than the cash price. Turnaround is two to four weeks. Genetic counselling is now widely available by telehealth; a single video session before testing is the standard of care. In the UK, NHS clinical genetics services provide testing free at the point of care when indication criteria are met; private testing runs roughly £400–£1,200.

Downstream costs, if you're a carrier, are larger but mostly insurance-shouldered: annual breast MRI is in the low thousands per scan before coverage, and risk-reducing surgery is a five-figure procedure reimbursed for documented carriers in most systems. The single-variant test for a relative once a family variant is known is the cheap one — typically $100 to $300, returned in days, and the most efficient cancer-prevention dollar in the literature.

What changes when you act on the result

Most takers of this test get the negative result they wanted and walk away. For them the payoff is fast: within a month, the multi-decade "what if" their family history was carrying gets archived, and their kids inherit the same archive. The yearly mammogram conversation goes back to being a yearly mammogram conversation, not a referendum.

For the smaller group who come back positive, the calendar of the next few decades reshapes immediately. Year one is scheduling — the first MRI, the surgical conversation, the cascade-testing conversation with siblings and adult children. By year two or three, for most carriers in their late thirties, the salpingo-oophorectomy decision lands; the trade is surgical menopause now for an actuarial life expectancy that climbs back toward population baseline Finch 2014 Domchek 2010. Ten and twenty years out is the part the numbers don't quite capture: the version of you who stays in your daughters' lives long past the age your mother left hers.

For the family, the cascade plays out in months, not years. Each first-degree relative gets a single-variant test that resolves in a week. Each one either steps off the worry list cleanly or steps onto the same screening calendar you did. The total amount of background dread carried by your gene pool drops a lot.

Related threads

A handful of nearby topics this entry deliberately doesn't cover. Hereditary cancer panels include other genes worth knowing about — PALB2, CHEK2, ATM, TP53 (Li-Fraumeni), and the Lynch-syndrome genes for colorectal and uterine risk. General-population breast cancer screening — mammography cadence, dense-breast supplemental imaging, breast self-exam — is a separate decision tree for everyone, carrier or not. Polygenic risk scores are an emerging technology that may refine breast cancer risk for the non-carrier majority. Insurance and privacy law specifics vary by country and by year, and are worth a fresh check before testing.

დაკავშირებული სახელმძღვანელოში

დაკავშირებული

— Ashkenazi Jewish ancestry carries founder BRCA mutations — a reason to consider this test specifically.
— A positive result means earlier, more intensive breast screening — and options well beyond it.
— BRCA testing is one slice of clinical genetic testing; a panel often checks it alongside related genes.
— A BRCA2 result changes prostate screening for men: start PSA earlier and take an elevated number more seriously.
— Carriers who choose risk-reducing ovary removal land in surgical menopause early. Plan the hormone-therapy conversation before, not after.

Substance + claimed effects

BRCA1/2 testing is a germline DNA test — usually a blood or saliva sample run on a multi-gene hereditary cancer panel — that looks for pathogenic or likely pathogenic variants in BRCA1 and BRCA2, the two best-characterised hereditary breast/ovarian cancer susceptibility genes. The substance is the test event plus the downstream care pathway it gates: counselling, result interpretation, intensified screening, risk-reducing surgery, targeted systemic therapy for diagnosed cancer, and cascade testing of blood relatives. Claimed effects, all of which the entry must score holistically: large reductions in breast and ovarian cancer mortality for confirmed carriers who act on the result Domchek 2010 Finch 2014; meaningful changes to surveillance intensity (annual contrast-enhanced breast MRI added to mammography from age 25–30) ACS 2007 NCCN v3.2024; eligibility for PARP inhibitors when cancer is diagnosed Robson 2017 Tutt 2021; non-trivial psychological burden and family-disclosure obligations; and a cascading effect across first-degree relatives whose own pretest probability of carrying the variant is 50%.

Evidence by addressing question

mechanism

Science / mechanism. BRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12) encode tumour-suppressor proteins central to homologous recombination repair of DNA double-strand breaks. A loss-of-function germline variant means every cell carries one broken copy from birth; somatic loss of the remaining functional allele in any breast or ovarian epithelial cell unleashes unrepaired DNA damage and accelerates carcinogenesis. This is why penetrance is high (the second hit is statistically inevitable across a lifetime of cell division) but stochastic (which cell, when). It also explains why PARP inhibitors work specifically in these tumours — blocking the parallel single-strand-break repair pathway produces synthetic lethality in cells already homologous-recombination-deficient Robson 2017. The test itself is straightforward Sanger sequencing or next-generation panel sequencing of the coding regions plus large rearrangement analysis; clinical labs now typically run multi-gene panels (BRCA1/2 plus PALB2, CHEK2, ATM, TP53, PTEN, CDH1 and others) on the same sample NCCN v3.2024.

evidence

Science. The penetrance numbers are the foundation. The largest prospective cohort to date — Kuchenbaecker et al., pooling 6,036 BRCA1 and 3,820 BRCA2 carriers — gave cumulative breast cancer risk to age 80 of 72% (95% CI 65–79) for BRCA1 carriers and 69% (61–77) for BRCA2 carriers, and cumulative ovarian cancer risk of 44% (36–53) for BRCA1 and 17% (11–25) for BRCA2 Kuchenbaecker 2017. Contralateral breast cancer risk at 20 years after first diagnosis was 40% (BRCA1) and 26% (BRCA2). Earlier family-based estimates were higher; case-series unselected for family history landed lower (Antoniou pooled analysis: 65% breast / 39% ovarian for BRCA1; 45%/11% for BRCA2 by age 70) Antoniou 2003. King's Ashkenazi-population cohort, which avoided the family-history ascertainment bias entirely, gave 82% breast cancer risk by age 80 for either gene and 54% (BRCA1) / 23% (BRCA2) ovarian King 2003. The honest range for shared counselling is roughly 55–80% lifetime breast and 20–45% lifetime ovarian, with BRCA1 ovarian risk markedly higher than BRCA2.

Outcomes after acting on the result. The PROSE consortium prospective cohort (Domchek et al., 2,482 carriers) is the canonical evidence that doing something with the result changes mortality. Risk-reducing salpingo-oophorectomy was associated with lower all-cause mortality (HR 0.40, 95% CI 0.26–0.61), lower breast-cancer-specific mortality (HR 0.44), and lower ovarian-cancer-specific mortality (HR 0.21). Risk-reducing mastectomy reduced subsequent breast cancer diagnosis from 7% to 0 over three years of follow-up Domchek 2010. Hartmann's earlier Mayo cohort gave breast cancer risk reduction of approximately 90% from bilateral prophylactic mastectomy in high-risk women Hartmann 1999. Finch's international prospective study of 5,783 carriers found a 77% reduction in all-cause mortality to age 70 after RRSO compared with no RRSO Finch 2014.

Targeted therapy unlocked by the result. Olaparib in BRCA-mutated metastatic HER2-negative breast cancer extended progression-free survival from 4.2 to 7.0 months versus chemotherapy in OlympiAD Robson 2017. OlympiA — adjuvant olaparib after standard treatment for high-risk early breast cancer in BRCA carriers — improved 3-year invasive disease-free survival from 77.1% to 85.9% (HR 0.58) and overall survival was significantly improved at the second interim analysis Tutt 2021. The testing result is therefore a gate to therapy that is otherwise unavailable.

Practice / consensus. USPSTF 2019 (Grade B) recommends primary care clinicians assess women with a personal or family history of breast/ovarian/tubal/peritoneal cancer or ancestry associated with BRCA1/2 variants, refer those who screen positive for genetic counselling, and offer testing if indicated USPSTF 2019. NCCN guidelines spell out specific personal-history triggers (breast cancer ≤50, triple-negative ≤60, male breast cancer, ovarian cancer at any age, pancreatic or metastatic prostate cancer, Ashkenazi Jewish ancestry plus any of the above) and family-history triggers (close relative with the same criteria) NCCN v3.2024.

protocol

Practice. Standard pathway: pre-test counselling with a certified genetic counsellor (in person or telehealth) → blood draw or saliva sample → multi-gene hereditary cancer panel run by a clinical laboratory (Myriad, Invitae, Ambry, GeneDx and others) → results returned in 2–4 weeks → post-test counselling. Result categories: pathogenic / likely pathogenic (positive), variant of uncertain significance (VUS — clinically equivalent to negative pending reclassification), or negative. True negative requires a known familial variant being excluded; an uninformative negative (no familial variant known) does not exclude inherited risk and is a major counselling point NCCN v3.2024.

Direct-to-consumer caveat. The FDA authorised 23andMe in 2018 to report three founder variants common in Ashkenazi populations (185delAG and 5382insC in BRCA1, 6174delT in BRCA2) FDA 2018. These represent <0.1% of pathogenic BRCA variants in non-Ashkenazi populations; a negative 23andMe BRCA result is uninformative for almost everyone outside that ancestry. Kurian et al. documented substantial under-testing of cancer patients who would benefit and noted that DTC results frequently require confirmation through a clinical laboratory Kurian 2019.

For confirmed carriers (NCCN). Breast surveillance: annual breast MRI from age 25 (BRCA1) or 25–30 (BRCA2), annual mammogram added from age 30, alternating roughly every six months so that imaging happens twice a year. Ovarian surveillance: no effective screening test exists; transvaginal ultrasound and CA-125 are offered at clinician discretion but do not reduce ovarian-cancer mortality. Risk-reducing salpingo-oophorectomy recommended at age 35–40 for BRCA1 carriers and 40–45 for BRCA2 carriers, ideally after childbearing complete. Risk-reducing mastectomy is offered, not recommended; the decision is the patient's NCCN v3.2024 Saslow 2007. Men: prostate screening from age 40 for BRCA2 carriers, breast self-exam awareness, pancreatic screening if a first-degree relative had pancreatic cancer.

contraindications

The test itself has essentially no medical contraindications — it is a blood or saliva sample. The relevant "don't" is procedural: do not test minors for adult-onset cancer predisposition (ASHG/AAP/ACMG consensus); do not order without pre-test counselling, because a positive result without context drives surgical decisions made under panic; and treat a negative DTC test as no test at all for non-Ashkenazi-founder questions FDA 2018. GINA (US Genetic Information Nondiscrimination Act, 2008) prohibits health insurance and employment discrimination on the basis of genetic results but does not cover life, disability, or long-term-care insurance — a real-world consideration for some patients in some jurisdictions.

misconceptions

Most cited mistakes from the clinical literature and counselling experience:

"No family history means no risk." Up to 50% of BRCA carriers identified through cancer-history-only criteria would have been missed by family-history screening alone Manchanda 2015; new mutations occur, fathers transmit equally, small families and early deaths obscure inheritance.
"A negative test means I'm in the clear." Only true if a known familial variant has been excluded. An uninformative negative still leaves the family-history risk in place — population-relative breast cancer risk for a woman with two affected first-degree relatives remains roughly 2–3x baseline.
"BRCA only affects women." Male BRCA2 carriers face elevated breast cancer (~7% lifetime), prostate cancer (~20%, often aggressive), and pancreatic cancer risk; BRCA1 male carriers have smaller but real prostate risk increases NCCN v3.2024.
"Mastectomy is the only option." Surveillance plus RRSO is a legitimate path; many carriers choose it and outcomes are good when adhered to.
"23andMe screens for BRCA." It screens for three founder variants. A clinical multi-gene panel sequences the entire coding region of BRCA1, BRCA2 and typically 7–80+ other genes.

audience

Three distinct audiences with different decision trees. Pre-cancer healthy carriers (the prevention case) are the largest and the cohort the surveillance/surgery literature targets. Newly diagnosed cancer patients need the result to gate PARP inhibitor eligibility and inform surgical decisions (contralateral mastectomy with the index procedure if positive); turnaround time matters — many centres now run "treatment-decision" panels with 7-day return. First-degree relatives of known carriers face a 50% prior probability and a much simpler test (single-site analysis of the known variant) that is cheap, fast, and definitive. Ethnic ancestry matters: Ashkenazi Jewish individuals carry one of the three founder variants at ~1 in 40 frequency versus ~1 in 400 general-population BRCA carrier rate King 2003 Manchanda 2015.

alternatives

Other testing modalities. Single-gene BRCA-only testing is now rarely the right call when multi-gene panels cost the same; PALB2 (lifetime breast cancer risk 35–50%), CHEK2, ATM, TP53 (Li-Fraumeni), PTEN (Cowden), CDH1 (lobular breast + diffuse gastric) all change management when found. Polygenic risk scores are emerging as a population-screening alternative or refinement but are not yet routine.

Other risk-reduction options for confirmed carriers. Tamoxifen reduces contralateral breast cancer in BRCA carriers (more clearly in BRCA2 than BRCA1), and is an alternative to mastectomy for some. Combined oral contraceptives reduce ovarian cancer risk by ~50% in BRCA carriers but slightly increase breast cancer risk — a tradeoff conversation. Salpingectomy followed by delayed oophorectomy is being studied as a way to reduce ovarian cancer risk without surgical menopause but is not standard NCCN v3.2024.

failure-modes

The recurring failure mode is the test happens, the result comes back, and nothing else does. Documented patterns: surveillance MRI started but not maintained when insurance reauthorisation lapses; RRSO declined and never revisited; cascade testing of relatives discussed once and then not followed up (only ~30–40% of eligible first-degree relatives complete cascade testing in most series) Daly 2017. The other failure mode is testing without a plan for results — particularly when ordered through DTC services or by clinicians without a genetics referral pathway. Variants of uncertain significance (~5–10% of results on broad panels) are routinely overinterpreted by patients and sometimes by non-specialists; they are not actionable until reclassified.

practicalities

In the US: clinical multi-gene panel typically $250 (cash-pay through Invitae/Ambry/Color) to $4,000+ depending on payer, with insurance covering testing when NCCN criteria are met (essentially always for indication-positive patients post-USPSTF). Turnaround 2–4 weeks; rush panels 7–10 days. Genetic counselling is widely available by telehealth (InformedDNA, Genome Medical, hospital-based programs); typical session 45–60 minutes. Direct-to-consumer (23andMe) ~$200 but limited; medical-grade DTC (Color, Nebula) $200–$500. UK NHS: indication-based testing free via regional clinical genetics services; private testing $500–$1,500. The wider hidden cost is downstream: annual MRI is expensive without coverage, and risk-reducing surgery is a five-figure procedure even when largely reimbursed.

history

BRCA1 cloned 1994 (Miki et al., University of Utah / Myriad collaboration); BRCA2 cloned 1995 (Wooster et al., UK). Myriad held exclusive US patents on the genes until the 2013 Supreme Court decision AMP v. Myriad invalidated patents on naturally occurring DNA sequences; testing prices fell roughly 75% within two years and multi-gene panels became standard. USPSTF first recommended BRCA risk assessment in 2005, broadened it in 2013, and refined to current form in 2019 USPSTF 2019. The high-profile cultural moment was Angelina Jolie's 2013 New York Times op-ed disclosing her BRCA1 result and bilateral mastectomy, which drove a documented surge in BRCA testing referrals globally — the "Jolie effect" — without obviously improving appropriateness of those referrals.

stakes

For a woman with a strong family history who skips testing: she faces ~70% lifetime breast and 20–45% lifetime ovarian cancer risk on the actuarial table, but more concretely, a 35–50% chance of being diagnosed with one of these cancers before age 50 if she's a BRCA1 carrier. Ovarian cancer is the loud signal here — most cases present at stage III/IV, five-year survival under 50%, and there is no effective screening test. Skipping the test forecloses the one intervention (RRSO) that demonstrably reduces ovarian-cancer mortality in carriers Finch 2014 Domchek 2010. For first-degree relatives of known carriers, skipping cascade testing keeps each relative at the 50/50 prior and removes the most cost-effective intervention in the entire cancer-prevention literature.

payoff

For a confirmed carrier who acts on the result, the actuarial outlook reshapes dramatically. RRSO at the recommended age reduces ovarian cancer incidence by 80% and breast cancer incidence by approximately 50% (when performed pre-menopause), and reduces all-cause mortality to age 70 by approximately 77% Finch 2014. Risk-reducing mastectomy reduces subsequent breast cancer by >90% Domchek 2010 Hartmann 1999. For a confirmed negative (true negative against a known familial variant), the gain is enormous: lifetime cancer risk returns to population baseline and intensive surveillance is no longer needed — emotional and economic relief that propagates across the family. The cascade effect is the multiplier: one proband's test result enables ~3–5 other relatives' targeted single-site tests, each one cheap, fast, and definitive.

out-of-scope

Mammography and breast self-exam protocols for the general-population woman; surgical technique and reconstructive choices for mastectomy; PARP inhibitor management in metastatic disease beyond eligibility gating; hereditary cancer syndromes outside the BRCA/Lynch axes (Li-Fraumeni, Cowden, Peutz-Jeghers); polygenic risk score implementation; insurance and privacy law specifics by jurisdiction.

The credibility range

Optimist case. BRCA1/2 testing is one of the highest-impact single interventions in preventive medicine for the population it identifies. The penetrance numbers are settled within a narrow band Kuchenbaecker 2017 Antoniou 2003; the surgical interventions are settled at large effect sizes that meet the bar of multiple prospective cohorts with consistent direction Domchek 2010 Finch 2014; PARP inhibitor benefit is RCT-grade and FDA-approved Robson 2017 Tutt 2021; cascade testing is the most cost-effective cancer prevention intervention quantified. Population testing in defined ancestral groups (Ashkenazi) appears to be cost-effective at conventional thresholds and identifies carriers missed by family-history criteria Manchanda 2015. There is no serious clinical debate about the value of testing the right person; the debate is who counts as "the right person."

Skeptic case. The population identified through current criteria is small (~0.25–0.5% of the general population are BRCA carriers), so the test is a very narrow-aperture intervention from a public-health standpoint. Penetrance estimates are family-ascertainment-biased upward; the truth for an unselected carrier with no family history is probably toward the lower end of the published range, which weakens the case for aggressive intervention in those incidentally identified Antoniou 2003. Psychosocial burden of carrier status is real and is sometimes inadequately captured in cost-effectiveness models. Surveillance MRI has high false-positive rates (~15% per round) with downstream biopsies, anxiety, and cost. Risk-reducing mastectomy and RRSO are irreversible with substantial QoL consequences — surgical menopause at 35–40 carries cardiovascular and bone-density consequences that the early survival numbers may not yet capture. Variants of uncertain significance are over-disclosed and over-acted-upon. DTC testing has created a stream of patients arriving at clinical genetics with positive results requiring confirmatory testing and counselling resources the system can't easily absorb Kurian 2019 FDA 2018.

Author's call. Testing is unambiguously high-value for anyone meeting NCCN/USPSTF criteria — the evidence on penetrance, on surgical risk reduction, and on therapy gating is among the strongest in cancer prevention. The honest entry frames it as a high-stakes, one-time decision with a clear pathway, and pushes hard on family-history triggers and cascade testing for relatives. Where the entry lands carefully: this is a decide action, not a do action — eligibility is the gate, and the decision to act on a positive result is genuinely consequential and personal. Evidence is high; controversy is low on the clinical question and moderate on the population-screening question.

Stakeholder + incentive map

Patient advocacy (FORCE — Facing Our Risk of Cancer Empowered; Bright Pink): strong push for broader testing access; aligned with carriers' lived experience but occasionally over-rotates on universal-screening advocacy.
Commercial testing labs (Myriad, Invitae, Ambry, GeneDx, Color): commercial incentive to expand the testable population; have driven price down dramatically post-Myriad ruling but also drove early VUS over-disclosure.
Direct-to-consumer (23andMe, AncestryHealth): consumer-product incentive, regulated FDA framing of three founder variants only; under-counsels, produces volume of positives needing confirmatory testing.
Guideline bodies (USPSTF, NCCN, ACMG, NSGC): consensus-building, conservative-by-design; USPSTF anchors primary-care behaviour, NCCN anchors specialist behaviour.
Insurers: coverage anchored to USPSTF and NCCN criteria; gatekeeping role on cost.
Counter-incentive: no large organised "anti-testing" camp; the genuine pushback is on over-testing, over-surgery, and over-interpretation of VUS, voiced by clinical geneticists and some primary-care physicians.

Population variability

Ancestry. Ashkenazi Jewish: ~1 in 40 carry one of three founder variants (185delAG, 5382insC in BRCA1; 6174delT in BRCA2). Some founder effects also documented in Icelandic (BRCA2 999del5), French-Canadian, Polish, and Hispanic populations. Sub-Saharan African ancestry has historically been under-represented in BRCA reference databases, increasing VUS rates King 2003.
Sex. BRCA1: dominant breast/ovarian risk in women; modest prostate risk in men. BRCA2: substantial male breast cancer (~7%), aggressive prostate cancer (~20%), and male and female pancreatic cancer risks.
Family-history-positive vs.-negative carriers. Penetrance is somewhat lower in carriers identified through population screening than in those identified through cancer family history. This matters for counselling pitched to the incidentally-identified.
Age. Risk accelerates from age 25 (BRCA1 breast) and 40 (BRCA1 ovarian); BRCA2 timing shifts later. Surveillance and surgical recommendations are gene-specific.
Reproductive history. Parity, breastfeeding, and oral contraceptive use modify both breast and ovarian risk in carriers in directions consistent with general-population patterns but with smaller absolute effect.

Knowledge gaps

Open questions: what is the true penetrance for BRCA carriers identified by population screening without family history (smaller cohorts, ongoing studies)? Does salpingectomy with delayed oophorectomy preserve the ovarian-cancer reduction benefit while avoiding surgical menopause? How should polygenic risk scores be integrated with BRCA status for breast cancer risk refinement? What is the long-term cardiovascular and cognitive cost of surgical menopause at 35–40, and does HRT to natural menopause age fully offset it? How should reclassification of VUS — which happens routinely as labs update their interpretations — be communicated to patients years after testing? Population screening trials in non-Ashkenazi general populations are limited; the cost-effectiveness case there is plausible but not yet established at guideline-changing strength.

Scoping calls. Brief named four downstream consequences (risk estimation, screening intensity, preventive surgery, family testing). Article covers each one end-to-end; none silently dropped. PARP-inhibitor eligibility is mentioned in the mechanism and evidence sections as the second thing a positive result gates, but the entry does not go deep on metastatic management — that belongs in a future oncology entry. The detailed surgical-technique and reconstruction conversation is also out of scope and noted in the closing section.

Action verb. Set to decide rather than do. The test is gated by eligibility criteria, and the post-positive surgical decisions are genuinely personal — framing it as a universal do would mislead the 99.5% of readers who don't meet criteria. Cadence is once; reclassification of a variant of uncertain significance years later is the only realistic recurrence and isn't a reason to re-test.

Rating difficulties. Longevity scored 5 — the surgical-intervention mortality numbers (Finch 2014, Domchek 2010) are among the largest hazard-ratio reductions in cancer prevention, but they apply only to the carrier subset. Decided the dimension is about the substance's effect on the population it identifies, not on the catalogue's average reader. Mood scored 2 (not higher) because the direction is mixed: true negatives gain relief, carriers gain dread plus a plan. Health (short-term) scored 0 — the test produces no felt-experience change in weeks. Beauty dimensions both 0 — risk-reducing mastectomy with reconstruction is real but not aesthetically directional and would be a wildly misleading place to anchor a beauty score.

Cost/effort framing. Scored against the typical-reader experience of taking the test (one panel, two counselling visits) rather than the lifetime-carrier downstream pathway, which would push both to 3+. Noted briefly inside the dimensions' justifications.

Future links to wire when entries land. Hereditary colorectal/Lynch syndrome, Li-Fraumeni / TP53, PALB2 and other moderate-penetrance breast genes, mammography cadence for general population, dense-breast supplemental screening, prostate cancer screening for BRCA2 men, polygenic risk scores, HRT after surgical menopause.

Separate-entry candidates. Risk-reducing salpingo-oophorectomy as its own decision entry; risk-reducing mastectomy as its own decision entry; cascade testing of relatives as a generalised pattern across hereditary syndromes.

Audience scoping. Left unscoped at the meta level despite the strong female skew of the downstream pathway. BRCA2 in particular has substantial male consequences (breast, prostate, pancreatic), and the misconceptions section pushes back on the "women's test" framing explicitly. Scoping to female would mis-signal.

Controversy. Held to 1. The clinical question — does testing benefit those meeting criteria — is settled. The active debates (population screening in non-Ashkenazi groups, RRSO timing, VUS handling, incidental positives) are margins, not paradigm fights. Noted in research §3c.